SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 117 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.53 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $65,805 | -36.9% | 4,532 | -9.1% | 0.04% | -35.5% |
| Q2 2023 | $104,294 | +19.9% | 4,983 | +20.9% | 0.06% | +29.2% |
| Q1 2023 | $87,014 | -40.0% | 4,120 | -27.7% | 0.05% | -36.8% |
| Q4 2022 | $145,090 | -8.7% | 5,701 | -14.0% | 0.08% | +20.6% |
| Q3 2022 | $159,000 | +25.2% | 6,628 | +0.7% | 0.06% | +34.0% |
| Q2 2022 | $127,000 | -16.4% | 6,584 | -24.5% | 0.05% | -30.9% |
| Q1 2022 | $152,000 | -24.8% | 8,723 | -5.6% | 0.07% | -10.5% |
| Q4 2021 | $202,000 | -6.0% | 9,238 | -17.8% | 0.08% | -20.0% |
| Q3 2021 | $215,000 | +5.9% | 11,241 | -5.0% | 0.10% | +14.5% |
| Q2 2021 | $203,000 | -23.1% | 11,835 | +0.1% | 0.08% | -25.9% |
| Q1 2021 | $264,000 | +1.9% | 11,828 | +1.8% | 0.11% | +4.7% |
| Q4 2020 | $259,000 | -11.9% | 11,624 | -41.6% | 0.11% | -30.5% |
| Q3 2020 | $294,000 | -12.2% | 19,894 | -12.0% | 0.15% | -3.1% |
| Q2 2020 | $335,000 | – | 22,596 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |